Diabetic Retinopathy - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 223 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Retinopathy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Diabetic Retinopathy - Pipeline Review, H1 2016', provides an overview of the Diabetic Retinopathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy
- The report reviews pipeline therapeutics for Diabetic Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Diabetic Retinopathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Diabetic Retinopathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Retinopathy Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Retinopathy - Overview 10
Pipeline Products for Diabetic Retinopathy - Comparative Analysis 11
Diabetic Retinopathy - Therapeutics under Development by Companies 12
Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Retinopathy - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Diabetic Retinopathy - Products under Development by Companies 19
Diabetic Retinopathy - Products under Investigation by Universities/Institutes 23
Diabetic Retinopathy - Companies Involved in Therapeutics Development 24
Acucela Inc. 24
Aerie Pharmaceuticals, Inc. 25
Aerpio Therapeutics, Inc. 26
Antisense Therapeutics Limited 27
BCN Peptides, S.A. 28
Biomar Microbial Technologies 29
Charlesson LLC. 30
Coherus BioSciences, Inc. 31
Crinetics Pharmaceuticals, Inc. 32
Diffusion Pharmaceuticals Inc. 33
Dimerix Bioscience Pty Ltd 34
Dynamis Therapeutics, Inc. 35
EyeGene, Inc. 36
Foresee Pharmaceuticals, LLC 37
GTx, Inc. 38
Icon Bioscience, Inc. 39
Islet Sciences, Inc. 40
Kodiak Sciences, Inc. 41
Kowa Company, Ltd. 42
LegoChem Biosciences, Inc 43
Lpath, Inc. 44
M's Science Corporation 45
Mabion SA 46
MingSight Pharmaceuticals 47
OcuCure Therapeutics, Inc. 48
Oculis ehf 49
Ohr Pharmaceutical Inc. 50
PanOptica, Inc. 51
Promedior, Inc. 52
Ribomic Inc. 53
Sirnaomics, Inc. 54
Stelic Institute & Co., Inc. 55
Stemedica Cell Technologies, Inc. 56
Strongbridge Biopharma plc 57
Sucampo Pharmaceuticals, Inc. 58
Targazyme, Inc. 59
ThromboGenics NV 60
TWi Pharmaceuticals, Inc. 61
UAB Profarma 62
VasGene Therapeutics, Inc. 63
Xbrane Biopharma AB 64
Diabetic Retinopathy - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 70
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
(irbesartan + propagermanium) - Drug Profile 77
A-717 - Drug Profile 79
AC-301 - Drug Profile 80
AKB-9778 - Drug Profile 81
ALG-1001 - Drug Profile 83
APTA-1004 - Drug Profile 85
Aptamers for Diabetic Retinopathy - Drug Profile 86
AR-13154 - Drug Profile 87
ATL-1103 - Drug Profile 88
Beta-LGND2 - Drug Profile 90
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 92
CLT-005 - Drug Profile 93
CLT-01001 - Drug Profile 94
CLT-01007 - Drug Profile 95
CLT-01012 - Drug Profile 96
CLT-020 - Drug Profile 97
COR-005 - Drug Profile 98
cyclosporine - Drug Profile 101
Cyndacel-M - Drug Profile 102
DMX-400 - Drug Profile 104
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 105
DT-23552 - Drug Profile 106
DYN-12 - Drug Profile 107
E-1086 - Drug Profile 109
EG-Mirotin - Drug Profile 110
emixustat hydrochloride - Drug Profile 112
FP-008 - Drug Profile 114
Granzyme B/VEGF - Drug Profile 115
IB-09A0133 - Drug Profile 116
IVMED-60 - Drug Profile 117
JP-153 - Drug Profile 118
KSI-301 - Drug Profile 119
L-779976 - Drug Profile 120
LCB-030110 - Drug Profile 122
Monoclonal Antibody for AMD, Diabetic Retinopathy and Oncology - Drug Profile 123
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile 124
MS-553 - Drug Profile 125
Nextomabs - Drug Profile 126
NM-108 - Drug Profile 127
OC-10X - Drug Profile 128
OC-410 - Drug Profile 129
ocriplasmin (recombinant) - Drug Profile 130
OCU-200 - Drug Profile 134
OCX-063 - Drug Profile 135
OLX-302 - Drug Profile 136
PAN-90806 - Drug Profile 137
PF-07 - Drug Profile 139
PRM-167 - Drug Profile 140
Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 141
ranibizumab biosimilar - Drug Profile 142
ranibizumab biosimilar - Drug Profile 143
ranibizumab biosimilar - Drug Profile 144
RBM-008 - Drug Profile 145
Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile 146
RES-529 - Drug Profile 147
ripasudil - Drug Profile 150
RTU-1096 - Drug Profile 152
somatostatin - Drug Profile 153
squalamine lactate - Drug Profile 154
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 157
Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 160
STNM-1510 - Drug Profile 161
STP-601 - Drug Profile 162
Synthetic Peptide to Agonize PEDF-R for Diabetic Retinopathy - Drug Profile 163
THR-687 - Drug Profile 164
TZ-101 - Drug Profile 165
V-1932 - Drug Profile 167
Vas-02 - Drug Profile 168
Diabetic Retinopathy - Recent Pipeline Updates 169
Diabetic Retinopathy - Dormant Projects 203
Diabetic Retinopathy - Discontinued Products 209
Diabetic Retinopathy - Product Development Milestones 210
Featured News & Press Releases 210
Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 217
Disclaimer 218

List of Tables

Number of Products under Development for Diabetic Retinopathy, H1 2016 15
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Development by Companies, H1 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Development, H1 2016 22
Comparative Analysis by Unknown Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Development by Companies, H1 2016 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2016 28
Diabetic Retinopathy - Pipeline by Acucela Inc., H1 2016 29
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016 30
Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc., H1 2016 31
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H1 2016 32
Diabetic Retinopathy - Pipeline by BCN Peptides, S.A., H1 2016 33
Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2016 34
Diabetic Retinopathy - Pipeline by Charlesson LLC., H1 2016 35
Diabetic Retinopathy - Pipeline by Coherus BioSciences, Inc., H1 2016 36
Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 37
Diabetic Retinopathy - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 38
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2016 39
Diabetic Retinopathy - Pipeline by Dynamis Therapeutics, Inc., H1 2016 40
Diabetic Retinopathy - Pipeline by EyeGene, Inc., H1 2016 41
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 42
Diabetic Retinopathy - Pipeline by GTx, Inc., H1 2016 43
Diabetic Retinopathy - Pipeline by Icon Bioscience, Inc., H1 2016 44
Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H1 2016 45
Diabetic Retinopathy - Pipeline by Kodiak Sciences, Inc., H1 2016 46
Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H1 2016 47
Diabetic Retinopathy - Pipeline by LegoChem Biosciences, Inc, H1 2016 48
Diabetic Retinopathy - Pipeline by Lpath, Inc., H1 2016 49
Diabetic Retinopathy - Pipeline by M's Science Corporation, H1 2016 50
Diabetic Retinopathy - Pipeline by Mabion SA, H1 2016 51
Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H1 2016 52
Diabetic Retinopathy - Pipeline by OcuCure Therapeutics, Inc., H1 2016 53
Diabetic Retinopathy - Pipeline by Oculis ehf, H1 2016 54
Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc., H1 2016 55
Diabetic Retinopathy - Pipeline by PanOptica, Inc., H1 2016 56
Diabetic Retinopathy - Pipeline by Promedior, Inc., H1 2016 57
Diabetic Retinopathy - Pipeline by Ribomic Inc., H1 2016 58
Diabetic Retinopathy - Pipeline by Sirnaomics, Inc., H1 2016 59
Diabetic Retinopathy - Pipeline by Stelic Institute & Co., Inc., H1 2016 60
Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 61
Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc , H1 2016 62
Diabetic Retinopathy - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 63
Diabetic Retinopathy - Pipeline by Targazyme, Inc., H1 2016 64
Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2016 65
Diabetic Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 66
Diabetic Retinopathy - Pipeline by UAB Profarma, H1 2016 67
Diabetic Retinopathy - Pipeline by VasGene Therapeutics, Inc., H1 2016 68
Diabetic Retinopathy - Pipeline by Xbrane Biopharma AB, H1 2016 69
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Stage and Target, H1 2016 73
Number of Products by Stage and Mechanism of Action, H1 2016 76
Number of Products by Stage and Route of Administration, H1 2016 79
Number of Products by Stage and Molecule Type, H1 2016 81
Diabetic Retinopathy Therapeutics - Recent Pipeline Updates, H1 2016 174
Diabetic Retinopathy - Dormant Projects, H1 2016 208
Diabetic Retinopathy - Dormant Projects (Contd..1), H1 2016 209
Diabetic Retinopathy - Dormant Projects (Contd..2), H1 2016 210
Diabetic Retinopathy - Dormant Projects (Contd..3), H1 2016 211
Diabetic Retinopathy - Dormant Projects (Contd..4), H1 2016 212
Diabetic Retinopathy - Dormant Projects (Contd..5), H1 2016 213
Diabetic Retinopathy - Discontinued Products, H1 2016 214